Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 3/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.42 |
| ▸ | DNM1 | Q05193 | 3/20 | 0.41 |
| ▸ | EP300 | Q09472 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1705800 | 1.00 | TSHR (0.62) | TSHRALDH1A1THRBFAAHTRPV1 | |
| SCHEMBL169329 | 1.00 | TSHR (0.62) | TSHRALDH1A1THRBFAAHTRPV1 | |
| SCHEMBL2871946 | 1.00 | TSHR (0.62) | TSHRALDH1A1THRBFAAHTRPV1 | |
| SCHEMBL3078400 | 1.00 | TSHR (0.62) | TSHRALDH1A1THRBFAAHTRPV1 | |
| SCHEMBL1076957 | 1.00 | TSHR (0.62) | TSHRALDH1A1THRBFAAHTRPV1 | |
| SCHEMBL2869472 | 1.00 | TSHR (0.62) | TSHRALDH1A1THRBFAAHTRPV1 | |
| SCHEMBL1395419 | 1.00 | TSHR (0.62) | TSHRALDH1A1THRBFAAHTRPV1 | |
| SCHEMBL10980289 | 1.00 | TSHR (0.62) | TSHRALDH1A1THRBFAAHTRPV1 | |
| SCHEMBL298912 | 1.00 | — | — | |
| SCHEMBL2859340 | 1.00 | TSHR (0.62) | TSHRALDH1A1THRBFAAHTRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10471127-B2 | Peptide pharmaceuticals for insulin resistance | MEDERIS DIABETES, LLC (US) | 2019-11-12 | — | — | US | claimed |
| CN-102138869-B | Peptide-based conditioner and colorant for hair, skin and nail | DU PONT | 2013-05-01 | — | — | CN | claimed |
| CN-101654476-A | Peptide-based body surface reagents for personal care | E I DU PONT DE NEMOURS CO US | 2010-02-24 | — | — | CN | claimed |
| CN-101218356-A | Methods of identifying skin binding peptides against skin care compositions | DU PONT (US) | 2008-07-09 | — | — | CN | claimed |
| EP-1708880-A2 | PLASTICS PIPE | UPONOR INNOVATION AB (SE) | 2006-10-11 | — | — | EP | claimed |
| WO-2005080077-A2 | PLASTICS PIPE | UPONOR INNOVATION AB (SE) | 2005-09-01 | — | — | WO | claimed |
| US-5369097-A | Glycerol backbone, quaternary ammonium compound | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 1994-11-29 | — | — | US | claimed |
| EP-4382137-A1 | NOVEL COMPOUND COMPRISING ESTER GROUP AND USES THEREOF | Kyungpook National University Industry-Academic Cooperation Foundation (KR) | 2024-06-12 | — | — | EP | disclosed |
| WO-2023144400-A1 | ANTIMICROBIAL INDICATOR COMPOSITION | TheUnseen Limited (GB) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023014119-A1 | NOVEL COMPOUND COMPRISING ESTER GROUP AND USES THEREOF | 경북대학교 산학협력단 | 2023-02-09 | — | — | WO | disclosed |
| US-10400339-B2 | Low water solubility compositions for use in corrosion protection | AGIENIC, INC. (US) | 2019-09-03 | — | — | US | disclosed |
| US-10392394-B2 | Antimicrobial compounds and methods | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) | 2019-08-27 | — | — | US | disclosed |
| US-20180291512-A1 | LOW WATER SOLUBILITY COMPOSITIONS FOR USE IN CORROSION PROTECTION | AGIENIC, INC. (US) | 2018-10-11 | — | — | US | disclosed |
| CN-1571828-A | Oil composition for cutting and grinding of trace oil supply type | NIPPON MITSUBISHI OIL CORP (JP) | 2005-01-26 | — | — | CN | disclosed |
| WO-2004042784-A2 | STABILIZED SEMICONDUCTOR NANOCRYSTALS | MASSACHUSSETTS INSTITUTE OF TECHNOLOGY (US) | 2004-05-21 | — | — | WO | disclosed |
| US-20040091710-A1 | Stabilized semiconductor nanocrystals | BB BIOVENTURES L.P. | 2004-05-13 | — | — | US | disclosed |
| US-6099730-A | REMOVING SUBSTANCES SUCH AS DRUGS AND TOXINS FROM WHOLE BLOOD. | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2000-08-08 | — | — | US | disclosed |
| WO-1999025463-A1 | APPARATUS AND METHOD FOR TREATING WHOLE BLOOD | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1999-05-27 | — | — | WO | disclosed |
| US-4153422-A | OIL SOLUBLE ETHYLENE-VINYL ACETATE COPOLYMER AND AN ALKYL ESTER OF OIL SOLUBLE ACRYLIC OR METHACRYLIC ACID | EXXON RESEARCH & ENGINEERING CO. (US) | 1979-05-08 | — | — | US | disclosed |
| US-4088589-A | Dual pour depressant combination for viscosity index improved waxy multigrade lubricants | EXXON RESEARCH & ENGINEERING CO. (US) | 1978-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10392394-B2 | Antimicrobial compounds and methods | GSDMD, AAAS, ACMSD | TSHR 4859/4885ALDH1A1 3082/4885THRB 4813/4885 |
| US-10471127-B2 | Peptide pharmaceuticals for insulin resistance | IAPP, GLP1R, PTMS | TSHR 192/4885ALDH1A1 4677/4885THRB 211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.